On January 27, 2022 Cardinal Health reported that it has earned the perfect score of 100% on the Human Rights Campaign Foundation’s Corporate Equality Index (CEI), a national benchmarking tool to measure corporate policies and practices related to LGBTQ+ (lesbian, gay, bisexual, transgender, queer and other) workplace equity (Press release, Cardinal Health, JAN 28, 2022, View Source [SID1234607466]). Organizations that have earned a 100% rating on the CEI have satisfied all criteria for the year and are recognized as a "Best Place to Work for LGBTQ+ Equality." This is the 14th year in a row that Cardinal Health has received a perfect score.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Diversity, equity and inclusion (DE&I) are core values of Cardinal Health. Employees at all levels of the company are committed to creating an inclusive workplace culture where every employee can bring 100% of themselves to work every day," said Steve Mason, CEO of Cardinal Health’s Medical segment and Executive Sponsor of the company’s PROUD employee resource group. "Earning 100% on the Corporate Equality Index for so many years tells us that we are on the right path and that what we are doing makes a difference."

A diverse, equitable and inclusive culture is also key to Cardinal Health’s innovation transformation, Mason said. "An inclusive culture is a kind of supercharger: it brings more creativity and innovation. Diverse teams find new ways to get things done, and solve problems more quickly, with better results."

Jay Brown, Human Rights Campaign senior vice president of programs, research and training, said, "We are proud that the Corporate Equality Index has paved the way for countless LGBTQ+ workers in America and abroad. But there is still more to do, which is why we are raising the bar yet again to create more equitable workplaces and a better tomorrow for LGBTQ+ workers everywhere. Congratulations to Cardinal Health for achieving the title of ‘best places to work for LGBTQ+ equality’ and working to advance inclusion in the workplace."

This is the 20th year of the CEI. This year’s CEI reflects growth across every measurement category, from the adoption of inclusive non-discrimination policies to equitable healthcare benefits for transgender employees.

The CEI rates companies on detailed criteria falling under four central pillars:

Non-discrimination policies across business entities;
Equitable benefits for LGBTQ+ workers and their families;
Supporting an inclusive culture; and,
Corporate social responsibility.
You can download the CEI report here, and read more about Cardinal Health’s DE&I work here.

On January 27, 2022 Optieum Biotechnologies reported that the company has been awarded "NEDO STS" grant from New Energy and Industrial Technology Development Organization (NEDO) (Press release, Optieum Biotechnologies, JAN 27, 2022, View Source [SID1234639138]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This grant was submitted with the support of ANRI, a venture capital. With this funding, we will continue to expand our platform technology and accelerate the development of in-house CAR-T cell programs.

We are committed to go beyond the limits of immuno-oncology drug development and deliver the most appropriate treatment for the cancer patients in needs.

On January 27, 2022 Thermo Fisher Scientific Inc., (NYSE:TMO), the world leader in serving science, reported that it received a score of 100 on the Human Rights Campaign Foundation’s 2022 Corporate Equality Index (CEI) for the seventh consecutive year (Press release, Thermo Fisher Scientific, JAN 27, 2022, View Source [SID1234608856]). As the national benchmarking tool measuring policies, practices and benefits pertinent to lesbian, gay, bisexual, transgender and queer (LGBTQ) employees, the CEI is a driving force for LGBTQ+ workplace inclusion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We truly believe that embracing diverse backgrounds and perspectives is vital to our long-term success as we work toward our shared mission of enabling our customers to make the world healthier, cleaner and safer," said Jennifer Farmer, vice president, global diversity and inclusion at Thermo Fisher Scientific. "Fostering an inclusive culture and a sense of belonging for our colleagues empowers them to contribute their best ideas and bring their true selves to work each day."

In 2002, the first year of the CEI, only 13 companies achieved a top-score. A record-breaking 842 businesses earned 100 percent on the 2022 CEI and the designation of being one of the "Best Places to Work for LGBTQ Equality," demonstrating the incredible impact the CEI has had on the business world over the last 20 years.

The CEI report measures performance across four categories, from the adoption of inclusive non-discrimination policies and equitable healthcare benefits for transgender employees to supporting an inclusive culture and corporate social responsibility. Thermo Fisher’s perfect score of 100 is based on its commitment to success within each of these important areas.

On January 27, 2022 Signify Health, Inc. (NYSE: SGFY), a leading value-based healthcare platform enabled by advanced analytics, technology and nationwide healthcare networks, reported that it will release its financial results for the fourth quarter 2021 after the market closes on Wednesday, March 2, 2022, and will hold a conference call at 8:30am ET on Thursday, March 3, 2022 to discuss the results (Press release, Signify Health, JAN 27, 2022, View Source [SID1234607607]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pre-registration is required for participation in the conference call. Please follow the link below to pre-register. After registering, you will be provided with your access details via email.

View Source

A webcast of the conference call will also be available live on the investor relations section of Signify Health’s website at View Source Please go to the website at least 15 minutes prior to the call to complete the registration process.

The webcast replay will be available through June 3, 2022 on Signify Health’s website at View Source

On January 27, 2022 Lupin Pharmaceuticals Inc., (Lupin) and Exeltis USA Inc. reported a promotional agreement for Exeltis to promote SOLOSEC along with Exeltis’ existing line of Women’s Health products, further enhancing value to OBGYNs and their patients (Press release, Lupin, JAN 27, 2022, View Source [SID1234607606]). SOLOSEC is indicated for the treatment of Bacterial Vaginosis in adult women (a common vaginal infection) and Trichomoniasis in adults (the most common non-viral, curable sexually transmitted infection in the U.S.).1-4

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This partnership will expand the reach of SOLOSEC, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC, and increase access for adult women suffering with bacterial vaginosis and adults with trichomoniasis," said Vinita Gupta, Chief Executive Officer of Lupin "We are extremely excited to partner with Exeltis." Salustiano Perez, Chief Executive Officer of Exeltis added, "Our team is thrilled to embark on this partnership. The addition of Solosec fits precisely within our current portfolio of products, enhancing our commercial strategy, and offering numerous solutions to our customers and their patients".

About SOLOSEC

SOLOSEC (secnidazole) 2 g oral granules is the first and only single-dose oral prescription approved to treat both bacterial vaginosis (BV), a common vaginal infection, in adult women and trichomoniasis, a sexually transmitted infection, in adults.1-4 SOLOSEC is designed to be easy to take and one oral dose contains a complete course of treatment.1

Additional information about SOLOSEC can be found at www.SOLOSEC.com.

INDICATION

SOLOSEC (secnidazole) 2 g oral granules is an antimicrobial agent indicated for the treatment of bacterial vaginosis in adult women and trichomoniasis in adults. Since trichomoniasis is a sexually transmitted disease, treat sexual partners of infected patients with the same dose and at the same time to prevent reinfection.

DOSAGE AND ADMINISTRATION

SOLOSEC is a single-dose therapy for oral use. The entire contents of SOLOSEC packet should be sprinkled onto applesauce, yogurt or pudding and consumed once within 30 minutes without chewing or crunching the granules. SOLOSEC is not intended to be dissolved in any liquid. Avoid consumption of alcoholic beverages and preparations containing ethanol or propylene glycol during treatment with SOLOSEC and for at least 2 days after completing therapy.

IMPORTANT SAFETY INFORMATION

SOLOSEC is contraindicated in patients with a history of hypersensitivity to secnidazole or other nitroimidazole derivatives.
Vulvovaginal candidiasis may develop with SOLOSEC and require treatment with an antifungal agent.
Potential risk of carcinogenicity is unknown and has not been studied in patients. Carcinogenicity has been seen in rodents chronically treated with nitroimidazole derivatives, which are structurally related to secnidazole. Chronic use should be avoided.
Breastfeeding is not recommended. Patients should discontinue breastfeeding for 96 hours after administration of SOLOSEC.
Most common adverse reactions observed in clinical trials (incidence ≥2%) were vulvovaginal candidiasis, headache, nausea, dysgeusia, vomiting, diarrhea, abdominal pain, and vulvovaginal pruritus.
To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-844-SOLOSEC (1-844-765-6732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Important Safety Information.

Or

Please click here for full Prescribing Information.

Manufactured for and Distributed by: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202

Marketed by: Exeltis USA, Inc., Florham Park, NJ 07932

SOLOSEC is a registered trademark owned by Lupin Inc.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management’s expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.